nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

15. Okuläre Beteiligung bei Stevens-Johnson-Syndrom (SJS) und Toxisch epidermaler Nekrolyse (TEN) (engl. Stevens-Johnson syndrome, SJS, and toxic epidermal necrolysis, TEN)

verfasst von : Argyrios Chronopoulos, Maja Mockenhaupt, Uwe Pleyer

Erschienen in: Entzündliche Augenerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

ICD-10-Code L12 Pemphigoiderkrankungen, L51.1 Erythema exsudativum multiforme; Stevens-Johnson-Syndrom; Toxisch epidermale Nekrolyse

Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, Kishimoto S, Kinoshita S (2009) Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 147(6):1004–1011PubMedCrossRef

Arévalo JM, Lorente JA, González-Herrada C, Jiménez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48:473–478PubMedCrossRef

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153PubMedCrossRef

Basu S, Pillai VS, Sangwan VS (2013) Mucosal complications of modified osteoodonto keratoprosthesis in chronic Stevens–Johnson syndrome. Am J Ophthalmol 156:867–873.e2PubMedCrossRef

Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS (2018) Chronic ocular sequelae of stevens-johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol 189:17–28PubMedCrossRef

Bohm KJ, Ciralsky JB, Harp JL, Bajaj S, Sippel KC (2016) Cicatrizing conjunctivitis in a patient diagnosed with drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome but with features of stevens-johnson syndrome. Cornea 35:888–891PubMedCrossRef

Catt CJ, Hamilton GM, Fish J et al (2016) Ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol 166:68–75PubMedCrossRef

Chung WH, Hung SI et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343–1350PubMedCrossRef

Creamer D, Walsh SA, Dziewulski P et al (2016) U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 174:1194–1227PubMedCrossRef

De La Paz MF, De Toledo JA, Charoenrook V et al (2011) Impact of clinical factors on the long-term functional and anatomic outcomes of osteo-odonto-keratoprosthesis and tibial bone keratoprosthesis. Am J Ophthalmol 151:829–839.e1CrossRef

De Rojas MV, Dart JK et al (2007) The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 91(8):1048–1053PubMedPubMedCentralCrossRef

Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous im-munoglobulins (IVIG). Clinical experience to date. Drugs 65(15):2085–2090PubMedCrossRef

González-Herrada C, Rodríguez-Martín S, Cachafeiro L et al (2017) Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol 137:2092–2100PubMedCrossRef

Gregory DG (2016) New grading system and treatment guidelines for the acute ocular manifestations of stevens-johnson syndrome. Ophthalmology 123:1653–1658PubMedCrossRef

Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M (2009). Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 145(2):157–162.

Gungor I, Schor K et al (2008) The Boston Scleral Lens in the treatment of pediatric patients. J AAPOS 12(3):263–267PubMedCrossRef

Haber J, Hopman W et al (2005) Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 26(1):33–41PubMedCrossRef

Huang Y-C, Li Y-C, Chen T-J (2012) The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 167:424–432PubMedCrossRef

Iyer G, Pillai VS, Srinivasan B et al (2010) Mucous membrane grafting for lid margin keratinization in Stevens–Johnson syndrome: results. Cornea 29:146–151PubMedCrossRef

Iyer G, Srinivasan B, Agarwal S et al (2014) Comprehensive approach to ocular consequences of Stevens Johnson Syndrome – the aftermath of a systemic condition. Graefes Arch Clin Exp Ophthalmol 252:457–467PubMedCrossRef

Iyer G, Srinivasan B, Agarwal S et al (2016) Treatment modalities and clinical outcomes in ocular sequelae of Stevens–Johnson syndrome over 25 years – a paradigm shift. Cornea 35:46–50PubMedCrossRef

Jain R, Sharma N, Basu S, Iyer G (2016) Stevens-Johnson syndrome: the role of an ophthalmologist. Surv Ophthalmol 61:369–399PubMedCrossRef

Kim DH, Yoon KC, Seo KY et al (2015) The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens–Johnson syndrome. Ophthalmology 122:254–264PubMedCrossRef

Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP (2014) Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71:941–947PubMedCrossRef

Kohanim S, Palioura S, Saeed HN et al (2016) Acute and chronic ophthalmic involvement in Stevens–Johnson syndrome/toxic epidermal necrolysis – a comprehensive review and guide to therapy. II Ophthalmic disease Ocul Surf 14:168–188PubMedCrossRef

Kuper K, Pleyer U et al (1995) Erythema exsudativum multiforme major. Ophthalmologe 92(6):823–828PubMed

Lee HY, Lim YL, Thirumoorthy T, Pang SM (2013) The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 169:1304–1309PubMedCrossRef

Lonjou C, Thomas L et al (2006) A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharm J 6(4):265–268

Lonjou C, Borot N et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99–107PubMedCrossRef

Ma KN et al (2016) A novel technique for amniotic membrane transplantation in patients with acute Stevens-Johnson syndrome. Ocul Surf 14:31–36PubMedCrossRef

Mockenhaupt M (2011) The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 7(6):814–815CrossRef

Mockenhaupt M, Roujeau JC (2019) Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Kang S, Amagai M, Bruckner A, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (Hrsg) Fitzpatrick’s dermatology, 9. Aufl. McGraw Hill Education, S 733–748, chapt. 44

Mockenhaupt M, Viboud C et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128(1):35–44PubMedCrossRef

Paulmann M, Mockenhaupt M (2019) Schwere Hautreaktionen: klinisches Bild, Epidemiologie, Ätiologie, Pathogenese und Therapie. Allergo J Int 28:311–326CrossRef

Oplatek A, Brown K et al (2006) Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 27(1):26PubMedCrossRef

Ong HS, Minassian D, Rauz S, Mehta JS, Dart JK (2019) Validation of a clinical assessment tool for cicatrising conjunctivitis. Ocul Surf pii: S1542-0124(19):30210–30211

Papakostas TD, Le HG, Chodosh J, Jacobs DS (2015) Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with a history of Stevens–Johnson syndrome/toxic epidermal necrolysis. Ophthalmology 122:248–253PubMedCrossRef

Paulmann M, Kremmler C, Sekula P, Valeyrie-Allanore L, Naldi L, Kardaun S, Mockenhaupt M for the RegiSCAR Group (2016) Long-term sequelae in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis. Allergy (Journal of the European Academy of Allergy and Clinical Immunology (EAACI)), link BioMedCentral platform 3.

Quinto GG, Campos M et al (2008) Autologous serum for ocular surface diseases. Arq Bras Oftalmol 71(6):47–54PubMedCrossRef

Romero-Rangel T, Stavrou P et al (2000) Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 130(1):25–32PubMedCrossRef

Rootman DB, Kim MJ, Aldave AJ et al (2015) Ocular surface, fornix, and eyelid rehabilitation in Boston type I keratoprosthesis patients with mucous membrane disease. Ophthal Plast Reconstr Surg 31:43–49PubMedCrossRef

Roujeau JC, Huynh TN et al (1987) Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123(9):1171–1173PubMedCrossRef

Roujeau JC, Mockenhaupt M, Guillaume JC, Revuz J (2017) New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Invest dermatol 137:2047–2049PubMedCrossRef

Roujeau JC, Mockenhaupt M (2019) Erythema multiforme. In: Kang S, Amagai M, Bruckner A, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (Hrsg) Fitzpatrick’s dermatology, 9. Aufl. McGraw Hill Education, S 723–732, chapt. 43

Roujeau JC, Phlippoteau C et al (1985) Sjögren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1(8429):609–611PubMedCrossRef

Rzany B, Mockenhaupt M et al (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773PubMedCrossRef

Saeed HN, Rashad R (2020) Ocular disease in Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Colby K, Dana R (Hrsg) Foundations of corneal disease. Springer, Berlin, Heidelberg S 97–108

Sharma N, Thenarasun SA, Kaur M et al (2016) Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome: a randomized control trial. Ophthalmology 123:484–491PubMedCrossRef

Sotozono C, Ueta M, Nakatani E et al (2015) Japanese Research committee on severe cutaneous adverse reaction. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 160:228–237PubMedCrossRef

Sotozono C, Ueta M, Yokoi N (2018) Severe dry eye with combined mechanisms is involved in the ocular sequelae of SJS/TEN at the chronic stage. Invest Ophthalmol Vis Sci 59:DES80–DES86PubMedCrossRef

Su S-C, Mockenhaupt M, Wolkenstein P et al (2017) Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 137:1065–1073PubMedCrossRef

Tougeron-Brousseau B, Delcampe A et al (2009) Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 148(6):852–859PubMedCrossRef

Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, Revuz J, Bagot M, Roujeau JC (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163:847–853PubMedCrossRef

Wang C-W, Yang L-Y, Chen C-B et al (2018) Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest 128:985–996PubMedPubMedCentralCrossRef

Weber SL, de Souza RB, Gomes JA, Hofling-Lima AL (2016) The use of the esclera scleral contact lens in the treatment of moderate to severe dry eye disease. Am J Ophthalmol 163:167–173.e1CrossRef

White KD, Abe R, Ardern-Jones M et al (2018) Special Article: SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract 6(1):38–69PubMedPubMedCentralCrossRef

Wolkenstein P, Latarjet J, Roujeau JC et al (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet Lond Engl 352:1586–1589CrossRef

Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY (2016) Long-term sequelae of stevens-johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 96(4):525–529PubMedCrossRef

Ziemer M, Mockenhaupt M (2011) Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. Skin Biopsy - Perspect. https://doi.org/10.5772/22335

Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M (2017) Systemic immunomodulating therapies for stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 153:514–522PubMedPubMedCentralCrossRef

Titel: Okuläre Beteiligung bei und Toxisch epidermaler Nekrolyse (engl. Stevens-Johnson syndrome, SJS, and toxic epidermal necrolysis, TEN)
verfasst von: Argyrios Chronopoulos
Maja Mockenhaupt
Uwe Pleyer
Verlag: Springer Berlin Heidelberg
Buch: Entzündliche Augenerkrankungen
Print ISBN: 978-3-662-60398-7

Electronic ISBN: 978-3-662-60399-4

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-60399-4_15

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

15. Okuläre Beteiligung bei Stevens-Johnson-Syndrom (SJS) und Toxisch epidermaler Nekrolyse (TEN) (engl. Stevens-Johnson syndrome, SJS, and toxic epidermal necrolysis, TEN)

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde